FR 173657: A new, potent, nonpeptide kinin B2 receptor antagonist: An in vitro study

Hypertension

Volumn 29, Issue 4, 1997, Pages 951-956

  Rizzi, Anna ^c   Gobeil, Fernand ^c   Calò, Girolamo ^c   Inamura, Noriaki ^a   Regoli, Domenico ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF FERRARA   (Italy)

^c NONE

Author keywords

biological assay; blood vessels; FR 173657; receptors, bradykinin; species specificity

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; ACETYLCHOLINE; ANGIOTENSIN; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; ENDOTHELIN 1; HISTAMINE; NORADRENALIN; SEROTONIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; COMPETITIVE INHIBITION; CORONARY ARTERY; FEMALE; GUINEA PIG; HUMAN TISSUE; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; SWINE;

EID: 0030982892     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.4.951     Document Type: Article

References (27)

1. Marceau F, Lussier A, Regoli D, Giroud JP. Pharmacology of kinins: their relevance to tissue injury and inflammation. Gen Pharmacol. 1983;14:209-229.
2. Dray A, Perkins M. Bradykinin and inflammatory pain. Trends Neurosci. 1993;16:99-104.
3. Vavrek RJ, Stewart JM. Competitive antagonists of bradykinin. Peptides. 1985;6:161-164.
4. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, Scholkens BA. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol. 1991;102:769-773.
5. Rhaleb NE, Rouissi N, Jukic D, Regoli D, Henke S, Breipohl G, Knolle J. Pharmacological characterization of a new highly potent B2 receptor antagonist (HOE 140: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin). Eur J Pharmacol. 1992;210:115-120.
6. Marceau F, Lévesque L, Drapeau G, Rioux F, Salvino JM, Wolfe HR, Seoane PR, Sawutz DG. Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin. J Pharmacol Exp Ther. 1994;269:1136-1143.
7. Félétou M, Martin CAE, Molimard M, Naline E, Germain M, Thurieau C, Fauchère JL, Canet E, Advenier C. In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pharmacol. 1995;274:57-64.
8. Gobeil F, Pheng LH, Badini I, Nguyen-Le XK, Pizard A, Rizzi A, Blouin D, Regoli D. Receptors for kinins in the human isolated umbilical vein. Br J Pharmacol. 1996;118:289-294.
9. Salvino JM, Seoane PR, Douty BD, Awad M, Dolle RE, Houck WT, Faunce DM, Sawutz DG. Design of potent non peptide competitive antagonists of the human bradykinin B2 receptor. J Med Chem. 1993;36:2583-2584.
10. Asano M, Inamura N, Hatori C, Sawai H, Fujisawa T, Kayagiri H, Sato S, Abe Y, Inoue T, Nakahara K, Oku T, Okuhara M. An orally active, nonpeptide bradykinin B2 receptor antagonist, FR 173657. Br J Pharmacol. 1997;120:617-624.
11. 2 antagonist. In vitro and in vivo studies. Abstract from the Symposium Proceedings: Peptide Receptors, VIII.0.3. Montreal, Canada, 1996.
12. Gaudreau P, Barabé J, St-Pierre S, Regoli D. Pharmacological studies of kinins on venous smooth muscles. Can J Physiol Pharmacol. 1981;59:371-379.
13. Furchgott RF, Bhadrakom S. Reactions of strips of rabbit aorta to epinephrine, isopropylarterenol, sodium nitrite and other drugs. J Pharmacol Exp Ther. 1953;108:129-143.
14. Rang HP. Stimulant actions of volatile anaesthetics on smooth muscle. Br J Pharmacol. 1964;22:356-365.
15. Pruneau D, Luccarini JM, Defrène E, Paquet JL, Bélichard P. Characterisation of bradykinin receptors from juvenile pig coronary artery. Eur J Pharmacol. 1996;297:53-60.
16. Regoli D, Barabé J, Park WK. Receptors of bradykinin in rabbit aorta. Can J Physiol Pharmacol. 1977;55:855-867.
17. Drapeau G, Regoli D. Synthesis of bradykinin analogs. Methods Enzymol. 1988;163:263-272.
18. Tallarida RJ, Murray RB. Manual of Pharmacologic Calculations With Computer Programs. New York, NY: Springer-Verlag; 1987: 121-125, 131-136.
19. Jenkinson DH, Barnard EA, Hover D, Humphrey PPA, Leff P, Shankley NP. International Union of Pharmacology Committee on receptor nomenclature and drug classification. IX: recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev. 1995;47:255-266.
20. Vanhoutte PM, Humphrey PPA, Spedding M. X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. Pharmacol Rev. 1996;48:1-2.
21. Schild HO. pA, a new scale for the measurement of drug antagonism. Br J Pharmacol. 1947;2:189-202.
22. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol. 1959;14:48-58.
23. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL, Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994;269:21583-21586.
24. Gobeil F, Regoli D. Characterization of kinin receptors by bioassays. Braz J Med Biol Res. 1994;27:1781-1791.
25. Griesbacher T, Legat FJ. The pharmacology of the non-peptide bradykinin antagonist FR 173657: in vitro and in vivo studies. Abstract from the Symposium Proceedings: Peptide Receptors, VIII.0.4. Montreal, Canada, 1996.
26. Regoli D, Boudon A, Fauchere JL. Receptors and antagonists for substance P and related peptides. Pharmacol Rev. 1994;46:551-599.
27. Félétou M, Germain M, Thurieau C, Fauchère JL, Canet E. Agonistic and antagonistic properties of the bradykinin B2 receptor antagonist, HOE 140, in isolated blood vessels from different species. Br J Pharmacol. 1994;112:683-687.